LAPATINIB (DITOSYLATE SALT)

Background Information:

An epidermal growth factor (EGFR) and HER2/neu (ErbB-2) dual tyrosine kinase inhibitor.

Reference:

1. Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga
CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated
transformation by heregulin production and activation of HER3. Oncogene.
2010 Jun 28. [Epub ahead of print] PubMed PMID: 20581867.
2. Nicoletta C, Lorenzo T, Anahi B, Raffaele P, Roberto M, Alberto B,
Debora S, Eva M, Alessio N, Silvio P. Dynamic Simulations of Pathways
Downstream of Erbb-Family, Including Mutations and Treatments.
Concordance with Experimental Results. Curr Cancer Drug Targets. 2010
Jun 25. [Epub ahead of print] PubMed PMID: 20578981.
3. Becze E. Manage diarrhea and skin effects from lapatinib. ONS Connect. 2010 Jun;25(6):12-3.

APIM050177: LAPATINIB (DITOSYLATE SALT)

CAS No.: 388082-78-8.
Molecular Formula: C29H26ClFN4O4S • 2C7H8O3S.
Molecular Weight: 925.5.
Purity: > 99% (HPLC).
QC: ¹HNMR, HPLC.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.